Market Research Report
Leadless Cardiac Pacemaker Market - Growth, Trends, and Forecasts (2020 - 2025)
|Published by||Mordor Intelligence LLP||Product code||391336|
|Published||Content info||90 Pages
Delivery time: 2-3 business days
|Leadless Cardiac Pacemaker Market - Growth, Trends, and Forecasts (2020 - 2025)|
|Published: June 1, 2020||Content info: 90 Pages||
Leadless cardiac pacemakers are medical devices that are used for the treatment of patients who are suffering from heart-related disorders, like arrhythmias. These pacemakers are expected to transform the cardiac rhythm management (CRM) market in the coming years with their potential to reduce complications and shorter recovery times.
Micra Transcatheter Pacing System is Expected to Witness Rapid Growth During the Forecast Period
In Leadless Cardiac Pacemaker Market, Nanostim and Micra TPS are key innovations. Both the devices are single-chamber pacemakers placed directly into the heart with a steerable catheter through the femoral vein. The procedure times with the Micra and Nanostim devices are shorter (lasting from 30 to 45 minutes), than those with the traditional pacemakers. They are self-contained intracardiac devices that include pacemaker electronics, battery, and leads. Both devices can be implanted in the same minimally invasive setting as some traditional pacemakers. Leadless pacemakers are expected to expand their market share rapidly, by displacing traditional cardiac pacemakers, during the forecast period. Micra transcatheter pacing system is in high demand due to rising burden of cardiovascular diseases, minimal post-implantation complications, and easy retrieval, which is expected to fuel the market. However, Abbott recalled its leadless pacemakers from the market following reports of sudden battery depletion. Moreover, in November 2017, Abbott issued a halt on implantations of Nanostim pacemakers, citing docking button issues, which continued till March 2018 but after fixing the issue, the company is working to relaunch the product.
North America is Expected to Dominate the Leadless Cardiac Pacemaker Market
The North American region is expected to dominate the leadless cardiac pacemaker market, due to the high prevalence of cardiovascular diseases, high adoption rates of leadless pacemakers, and availability of reimbursements. furthermore, owing to increasing number of patients suffering from atrial fibrillation and presence of major players in the region is also expected to propel the market growth, over the forecast period.
Medical device companies actively participating in the leadless cardiac pacemakers market are Medtronic, EBR Systems Inc, Abbott Laboratories and Boston Scientific Corporation. As of 2019, the leadless pacemaker systems commercially available in the market, having slightly different sizes and implantation requirements, which are Nanostim (Abbott Laboratories) and Micra (Medtronic PLC) and WiSE CRT system (EBR Systems Inc.). However, Boston Scientific, one of the leading pacemaker manufacturers, has been developing its own leadless pacemaker system.